Pierre F Desreumaux

List of Publications by Citations

211 papers	19,011 citations	65 h-index	135 g-index
273 ext. papers	21,622 ext. citations	8.3 avg, IF	5.95 L-index

#	Paper	IF	Citations
211	Vedolizumab as induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine*, **2013**, 369, 699-710	59.2	1465
210	Vedolizumab as induction and maintenance therapy for Crohn's disease. *New England Journal of Medicine*, **2013**, 369, 711-21	59.2	1328
209	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. *New England Journal of Medicine*, **2016**, 375, 1946-1960	59.2	896
208	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet, The*, **2009**, 374, 1617-25	40	792
207	Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. *Gastroenterology*, **1998**, 115, 1405-13	13.3	640
206	Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. *Nature Medicine*, **2007**, 13, 35-7	50.5	612
205	Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. *Nature Medicine*, **1998**, 4, 1053-7	50.5	530
204	Dysbiosis in inflammatory bowel disease. *Gut*, **2004**, 53, 1-4	19.2	490
203	CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. *Journal of Clinical Investigation*, **2007**, 117, 1566-74	15.9	395
202	Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. *Journal of Experimental Medicine*, **2001**, 193, 827-38	16.6	371
201	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. *Journal of Experimental Medicine*, **2005**, 201, 1205-15	16.6	361
200	Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. *Gastroenterology*, **2011**, 141, 1621-28.e1-5	13.3	337
199	Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. *Gastroenterology*, **2003**, 124, 1265-76	13.3	329
198	PPARgamma as a new therapeutic target in inflammatory bowel diseases. *Gut*, **2006**, 55, 1341-9	19.2	295
197	A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. *Molecular Cell*, **2001**, 8, 737-47	17.6	264
196	Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. *Gastroenterology*, **1999**, 117, 73-81	13.3	260
195	Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. *Gastroenterology*, **2012**, 143, 1207-1217.e2	13.3	253

194	Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. *Journal of Experimental Medicine*, **1994**, 179, 703-8	16.6	243
193	Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease?. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 13306-11	11.5	232
192	Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. *American Journal of Gastroenterology*, **2002**, 97, 939-46	0.7	226
191	Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. *Journal of Experimental Medicine*, **1992**, 175, 293-6	16.6	217
190	Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. *Gastroenterology*, **2000**, 118, 867-79	13.3	195
189	Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 2977-82	11.5	194
188	Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. *Gastroenterology*, **1997**, 113, 118-26	13.3	192
187	Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. *Alimentary Pharmacology and Therapeutics*, **2006**, 24 Suppl 1, 2-9	6.1	187
186	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. *Gastroenterology*, **2016**, 150, 1568-1578	13.3	171
185	Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. *Gut*, **2012**, 61, 78-85	19.2	171
184	Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. *Diabetologia*, **2000**, 43, 1165-9	10.3	171
183	Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. *Gastroenterology*, **2005**, 128, 334-42	13.3	169
182	Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. *Gastroenterology*, **2003**, 125, 795-804	13.3	162
181	Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. *Lancet, The*, **2002**, 360, 1410-8	40	162
180	Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. *Gut*, **2007**, 56, 577-83	19.2	160
179	Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. *Gut*, **2001**, 49, 42-6	19.2	158
178	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 8772-7	11.5	154
177	Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. *Gastroenterology*, **1996**, 110, 768-74	13.3	141

176	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1593-1601.e2	6.9	141
175	Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. *Journal of Medicinal Chemistry*, **2012**, 55, 4027-61	8.3	130
174	Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 1048-55	6.9	127
173	Anti-inflammatory properties of the δ opioid receptor support its use in the treatment of colon inflammation. *Journal of Clinical Investigation*, **2003**, 111, 1329-1338	15.9	127
172	Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. *Journal of Infectious Diseases*, **2008**, 197, 972-80	7	126
171	Natural history of eosinophilic gastroenteritis. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 950-956.e1	6.9	118
170	Mucin gene expression in intestinal epithelial cells in Crohn's disease. *Gut*, **2001**, 49, 544-51	19.2	113
169	LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 13098-103	11.5	111
168	Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. *Gut*, **2003**, 52, 840-6	19.2	111
167	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. *American Journal of Gastroenterology*, **2017**, 112, 337-345	0.7	104
166	Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. *Vaccine Journal*, **2003**, 10, 696-701		99
165	Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. *Gastroenterologie Clinique Et Biologique*, **2003**, 27, 987-91		98
164	Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. *Cellular Microbiology*, **2007**, 9, 1252-61	3.9	97
163	Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. *Gastroenterology*, **2006**, 130, 1962-74	13.3	96
162	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. *Gut*, **2014**, 63, 1416-23	19.2	94
161	Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma. *Journal of Experimental Medicine*, **1995**, 182, 1897-904	16.6	94
160	Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2012**, 18, 1199-206	4.5	91
159	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 310-321	6.1	85

158	Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. *Gut*, **1995**, 37, 242-6	19.2	81
157	Crohn's disease: beyond antagonists of tumour necrosis factor. *Lancet, The*, **2008**, 372, 67-81	40	80
156	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2012**, 18, 2063-71	4.5	77
155	Genetically related Escherichia coli strains associated with Crohn's disease. *Gut*, **2001**, 48, 320-5	19.2	77
154	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 252-61	6.1	77
153	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). *Gut*, **2019**, 68, 40-48	19.2	75
152	Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 533-43	6.1	72
151	Resistin-like molecule beta regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. *Inflammatory Bowel Diseases*, **2008**, 14, 931-41	4.5	67
150	Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. *Gut*, **2006**, 55, 815-23	19.2	66
149	CD8+ cytotoxic T cells induce relapsing colitis in normal mice. *Gastroenterology*, **2006**, 131, 485-96	13.3	66
148	Bacteriophages Targeting Adherent Invasive Escherichia coli Strains as a Promising New Treatment for Crohn's Disease. *Journal of Crohn's and Colitis*, **2017**, 11, 840-847	1.5	65
147	Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. *Journal of Clinical Investigation*, **2003**, 111, 1329-38	15.9	65
146	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. *Mucosal Immunology*, **2014**, 7, 589-601	9.2	63
145	Obesity, visceral fat and Crohn's disease. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2010**, 13, 574-80	3.8	63
144	A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. *Digestive and Liver Disease*, **2015**, 47, 119-24	3.3	62
143	Eosinophils in allergic reactions. *Current Opinion in Immunology*, **1996**, 8, 790-5	7.8	62
142	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 485-493	6.1	61
141	Abnormalities in mucin gene expression in Crohn's disease. *Inflammatory Bowel Diseases*, **1999**, 5, 24-32	4.5	61

140	Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. *World Journal of Gastroenterology*, **2005**, 11, 7591-6	5.6	58
139	Visceral fat and gut inflammation. *Nutrition*, **2012**, 28, 113-7	4.8	55
138	GW501516-activated PPAR promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. *Cell and Bioscience*, **2012**, 2, 34	9.8	52
137	Novel PPAR Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis. *Inflammatory Bowel Diseases*, **2016**, 22, 279-92	4.5	51
136	Switching invariant natural killer T (iNKT) cell response from anticancerous to anti-inflammatory effect: molecular bases. *Journal of Medicinal Chemistry*, **2014**, 57, 5489-508	8.3	50
135	The role of PPAR mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology. *Experimental Dermatology*, **2015**, 24, 245-51	4	50
134	Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. *British Journal of Dermatology*, **1995**, 132, 479-82	4	50
133	Probiotics in inflammatory bowel disease: a critical review. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2003**, 17, 805-20	2.5	49
132	Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease. *Transplantation*, **2004**, 78, 1697-701	1.8	49
131	5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. *World Journal of Gastroenterology*, **2005**, 11, 309-14	5.6	48
130	Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. *Inflammatory Bowel Diseases*, **2009**, 15, 1476-84	4.5	47
129	Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. *Gut*, **2002**, 50, 25-8	19.2	47
128	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 892-899.e2	6.9	45
127	Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. *American Journal of Physiology - Renal Physiology*, **2014**, 307, G274-85	5.1	45
126	Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine. *American Journal of Gastroenterology*, **2007**, 102, 1108-15	0.7	45
125	Novel polymeric film coatings for colon targeting: Drug release from coated pellets. *European Journal of Pharmaceutical Sciences*, **2009**, 37, 427-33	5.1	44
124	Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. *Leukemia*, **2002**, 16, 1637-44	10.7	43
123	PPAR-gamma in ulcerative colitis: a novel target for intervention. *Current Drug Targets*, **2013**, 14, 1501-73		43

122	NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation. *Trends in Microbiology*, **2006**, 14, 432-8	12.4	41
121	Effects of urban coarse particles inhalation on oxidative and inflammatory parameters in the mouse lung and colon. *Particle and Fibre Toxicology*, **2017**, 14, 46	8.4	39
120	O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn Disease Refractory to Anti-TFN *Inflammatory Bowel Diseases*, **2016**, 22, S1	4.5	39
119	Decreased lymphatic vessel density is associated with postoperative endoscopic recurrence in Crohn's disease. *Inflammatory Bowel Diseases*, **2013**, 19, 2084-90	4.5	38
118	NOD2: a potential target for regulating liver injury. *Laboratory Investigation*, **2008**, 88, 318-27	5.9	38
117	Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. *Inflammatory Bowel Diseases*, **2000**, 6, 157-64	4.5	38
116	IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. *Journal of Clinical Investigation*, **2019**, 129, 1910-1925	15.9	38
115	Preclinical studies of a specific PPAR modulator in the control of skin inflammation. *Journal of Investigative Dermatology*, **2014**, 134, 1001-1011	4.3	37
114	Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 924-932	6.1	35
113	3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 5383-94	3.4	34
112	CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. *World Journal of Gastroenterology*, **2017**, 23, 336-344	5.6	32
111	Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier. *Scientific Reports*, **2015**, 5, 9577	4.9	32
110	New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 3777-86	3.4	32
109	The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils. *Mucosal Immunology*, **2016**, 9, 322-35	9.2	31
108	Intestinal steroidogenesis controls PPAR expression in the colon and is impaired during ulcerative colitis. *Gut*, **2015**, 64, 901-10	19.2	31
107	In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy. *Journal of Controlled Release*, **2015**, 197, 121-30	11.7	31
106	Similar IL-5, IL-3, and GM-CSF syntheses by eosinophils in the jejunal mucosa of patients with celiac disease and dermatitis herpetiformis. *Clinical Immunology and Immunopathology*, **1998**, 88, 14-21		31
105	Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. *Alimentary Pharmacology and Therapeutics*, **2006**, 24, 851-8	6.1	31

104	Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control. *Gastroenterology*, **2010**, 138, 1546-56, 1556.e1-5	13.3	30
103	Epithelial inflammation response induced by Shigella flexneri depends on mucin gene expression. *Microbes and Infection*, **2002**, 4, 1121-4	9.3	30
102	Role of the high affinity immunoglobulin E receptor in bacterial translocation and intestinal inflammation. *Journal of Experimental Medicine*, **2001**, 193, 25-34	16.6	30
101	Preliminary study of urinary schistosomiasis in a village in the delta of the Senegal river basin, Senegal. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **1994**, 88, 401-5	2	30
100	How NOD2 mutations predispose to Crohn's disease?. *Microbes and Infection*, **2007**, 9, 658-63	9.3	29
99	AIEC colonization and pathogenicity: influence of previous antibiotic treatment and preexisting inflammation. *Inflammatory Bowel Diseases*, **2012**, 18, 1923-31	4.5	28
98	4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series. *Journal of Medicinal Chemistry*, **2010**, 53, 7918-31	8.3	28
97	Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases. *Inflammatory Bowel Diseases*, **2013**, 19, 2315-25	4.5	27
96	Colon targeting with bacteria-sensitive films adapted to the disease state. *European Journal of Pharmaceutics and Biopharmaceutics*, **2009**, 73, 74-81	5.7	27
95	Advances and perspectives in the genetics of inflammatory bowel diseases. *Clinical Gastroenterology and Hepatology*, **2006**, 4, 143-51	6.9	27
94	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 533-541	6.1	26
93	No evidence for an involvement of the p38 and JNK mitogen-activated protein in inflammatory bowel diseases. *Digestive Diseases and Sciences*, **2006**, 51, 1443-53	4	26
92	Cerebro-spinal fluid eosinophilia in shunt infections. *Neuropediatrics*, **1992**, 23, 235-40	1.6	26
91	Role of glycogen synthase kinase-3 and PPAR- in epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis. *PLoS ONE*, **2017**, 12, e0171093	3.7	25
90	Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents. *Current Medicinal Chemistry*, **2012**, 19, 3457-74	4.3	25
89	Evidence for eosinophil activation in eosinophilic cystitis. *European Urology*, **1994**, 25, 254-8	10.2	25
88	The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPAR *Carcinogenesis* , **2013**, 34, 2580-6	4.6	24
87	Colonic inflammation in mice is improved by cigarette smoke through iNKT cells recruitment. *PLoS ONE*, **2013**, 8, e62208	3.7	24

86	Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD). *Clinical and Experimental Immunology*, **2000**, 122, 180-5	6.2	23
85	Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. *Journal of Immunology*, **2000**, 165, 202-10	5.3	23
84	Toxicological consequences of experimental exposure to aluminum in human intestinal epithelial cells. *Food and Chemical Toxicology*, **2016**, 91, 108-16	4.7	23
83	Intestinal steroidogenesis. *Steroids*, **2015**, 103, 64-71	2.8	22
82	Novel polymeric film coatings for colon targeting: how to adjust desired membrane properties. *International Journal of Pharmaceutics*, **2009**, 371, 64-70	6.5	22
81	micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. *Gut*, **2007**, 56, 974-81	19.2	22
80	Infliximab failure in cap polyposis. *Gut*, **2005**, 54, 313-4	19.2	22
79	Pyrogenicity and cytokine-inducing properties of Streptococcus pyogenes superantigens: comparative study of streptococcal mitogenic exotoxin Z and pyrogenic exotoxin A. *Infection and Immunity*, **2001**, 69, 4141-5	3.7	22
78	Search for evidence of recurring or persistent viruses in Crohn's disease. *Apmis*, **2007**, 115, 962-8	3.4	21
77	Gut: An underestimated target organ for Aluminum. *Morphologie*, **2016**, 100, 75-84	0.9	21
76	Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis. *ACS Medicinal Chemistry Letters*, **2015**, 6, 198-203	4.3	20
75	4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis. *Journal of Medicinal Chemistry*, **2012**, 55, 8948-52	8.3	20
74	Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn's Disease Patients Classified i2 on the Rutgeerts Score. *Digestive Diseases and Sciences*, **2016**, 61, 2986-2992	4	20
73	Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn's disease and anti-saccharomyces cerevisiae antibody levels. *Inflammatory Bowel Diseases*, **2012**, 18, 430-8	4.5	18
72	Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. *Inflammatory Bowel Diseases*, **1999**, 5, 174-81	4.5	18
71	Eosinophilic enteritis. *Digestive Diseases*, **2015**, 33, 183-189	3.2	17
70	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating α4β7+ T Cells in Crohn's Disease: Report of the TOSCA Study. *Journal of Crohn's and Colitis*, **2018**, 12, 188-196	1.5	17
69	Peroxisome proliferator-activated receptor gamma in the colon: inflammation and innate antimicrobial immunity. *Journal of Clinical Gastroenterology*, **2014**, 48 Suppl 1, S23-7	3	17

68	Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features. *Chemical Biology and Drug Design*, **2013**, 81, 442-54	2.9	17
67	Streptococcal pyrogenic exotoxin A (SPE A) superantigen induced production of hematopoietic cytokines, IL-12 and IL-13 by human peripheral blood mononuclear cells. *Microbial Pathogenesis*, **1997**, 23, 265-72	3.8	17
66	Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic Review. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 847-856	6.9	17
65	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. *Gut*, **2017**, 66, 1912-1917	19.2	16
64	Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. *European Journal of Gastroenterology and Hepatology*, **1999**, 11, 1113-9	2.2	16
63	Peroxisome proliferator-activated receptor gamma (PPARγ) regulates lactase expression and activity in the gut. *EMBO Molecular Medicine*, **2017**, 9, 1471-1481	12	15
62	Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. *Inflammatory Bowel Diseases*, **2017**, 23, 1853-1859	4.5	15
61	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence. *Journal of Crohn's and Colitis*, **2017**, 11, 281-288	1.5	14
60	Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. *Journal of Crohn's and Colitis*, **2017**, 11, 1326-1334	1.5	14
59	Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. *Journal of Pharmacy and Pharmacology*, **2010**, 62, 1676-84	4.8	14
58	Short-term variability of intertidal microphytobenthic production using an oxygen microprofiling system. *Marine and Freshwater Research*, **2009**, 60, 712	2.2	14
57	Peas starch-based film coatings for site-specific drug delivery to the colon. *Journal of Applied Polymer Science*, **2011**, 119, 1176-1184	2.9	13
56	Specific targeting of IL-6 signalling pathway: a new way to treat IBD?. *Gut*, **2000**, 47, 465-6	19.2	13
55	Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. *European Journal of Gastroenterology and Hepatology*, **2018**, 30, 1247-1252	2.2	13
54	Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study. *Inflammatory Bowel Diseases*, **2019**, 25, 394-402	4.5	12
53	Characterization of ethylcellulose: starch-based film coatings for colon targeting. *Drug Development and Industrial Pharmacy*, **2009**, 35, 1190-200	3.6	12
52	Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. *Digestive and Liver Disease*, **2017**, 49, 163-169	3.3	11
51	Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lémann Index and Inflammatory Bowel Disease Disability Index. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 889-898	6.1	11

50	Switching cannabinoid response from CB(2) agonists to FAAH inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1322-6	2.9	11
49	Immunobiology of eosinophils in allergy and inflammation. *Research in Immunology*, **1997**, 148, 29-33		11
48	Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease. *Digestive Diseases and Sciences*, **2020**, 65, 1445-1452	4	10
47	Yersinia pseudotuberculosis anti-inflammatory components reduce trinitrobenzene sulfonic acid-induced colitis in the mouse. *Infection and Immunity*, **2004**, 72, 2438-41	3.7	9
46	Overexpression of IL-10 mRNA in gut mucosa of patients with allergic asthma. *Journal of Allergy and Clinical Immunology*, **2001**, 107, 739-41	11.5	9
45	Superantigenic Yersinia pseudotuberculosis induces the expression of granzymes and perforin by CD4+ T cells. *Infection and Immunity*, **2015**, 83, 2053-64	3.7	8
44	Acrylamide induces accelerated endothelial aging in a human cell model. *Food and Chemical Toxicology*, **2015**, 83, 140-5	4.7	8
43	The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis. *Frontiers in Immunology*, **2017**, 8, 1052	8.4	8
42	In vivo imaging reveals selective PPAR activity in the skin of peroxisome proliferator-activated receptor responsive element-luciferase reporter mice. *Experimental Dermatology*, **2013**, 22, 137-40	4	8
41	Overexpression of leptin mRNA in the mesenteric adipose tissue of inflammatory bowel disease (IBD). *Gastroenterology*, **2000**, 118, A340-A341	13.3	8
40	CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal mucosa in Crohn disease. *Human Immunology*, **2001**, 62, 694-700	2.3	8
39	Infectious agents and Crohn's disease. *Clinical Microbiology and Infection*, **1999**, 5, 601-4	9.5	8
38	Mixed adenocarcinoid tumor and Crohn's disease. *Journal of Clinical Gastroenterology*, **1998**, 26, 353-4	3	8
37	Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses. *PLoS ONE*, **2018**, 13, e0209681	3.7	8
36	High carriage of adherent invasive in wildlife and healthy individuals. *Gut Pathogens*, **2018**, 10, 23	5.4	7
35	Impaired contractile response of mesenteric arteries in Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2000**, 14, 1279-85	6.1	7
34	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. *Gastroenterology*, **2016**, 150, S155	13.3	6
33	Evaluation of therapeutic properties of fermented vegetables extract (OM-X) in the model of colitis induced by Citrobacter rodentium in mice. *Journal of Functional Foods*, **2014**, 10, 117-127	5.1	6

32	OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study. *Journal of Crohn's and Colitis*, **2014**, 8, S4-S5	1.5	6
31	Enzymatically activated coated multiparticulates containing theophylline for colon targeting. *Journal of Drug Delivery Science and Technology*, **2010**, 20, 193-199	4.5	6
30	PPARgamma agonists as a new class of effective treatment for ulcerative colitis. *Inflammatory Bowel Diseases*, **2009**, 15, 959-60	4.5	6
29	Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 1652-1660	6.1	5
28	Hepatic deficiency of interleukin 10 in chronic hepatitis C. *Gastroenterology*, **2000**, 119, 1411-2	13.3	5
27	Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis. *Gut*, **1995**, 37, 132-5	19.2	5
26	Using a Sodar to Measure Optical Turbulence and Wind Speed for the Thirty Meter Telescope Site Testing. Part I: Reproducibility. *Boundary-Layer Meteorology*, **2011**, 141, 273-288	3.4	4
25	Saccharomyces Cerevisiae CNCM I-3856 Reduces Digestive Discomfort and Abdominal Pain in Subjects With Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo-Controlled Clinical Trial. *Gastroenterology*, **2011**, 140, S-50	13.3	3
24	274 Sacharomyces Cerevisiae Cncm I-3856 Decreases Intestinal Pain Through PPAR Alpha Activation in the Gut. *Gastroenterology*, **2010**, 138, S-51	13.3	3
23	La gastroentérite à éosinophiles. *Revue Francaise D'allergologie*, **2010**, 50, 248-253	0.2	3
22	Virulence factors of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). *Gastroenterology*, **1998**, 114, A958-A959	13.3	3
21	741 4-Oxo-1,4-Dihydroquinoline-3-Carboxamides Derivatives As New Potent and Selective Cb2 Agonists with Anti-Inflammatory and Analgesic Properties in the Gut. *Gastroenterology*, **2008**, 134, A-107	13.3	3
20	Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases. *European Journal of Anaesthesiology*, **2003**, 20, 957-962	2.3	3
19	Invasive ability of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). *Gastroenterology*, **2000**, 118, A342	13.3	3
18	GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. *Cellular and Molecular Immunology*, **2020**, 17, 1272-1274	15.4	2
17	Sa1960 Crohn's Disease Patients With High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. *Gastroenterology*, **2016**, 150, S417	13.3	2
16	Preclinical Evaluation of Intestinal Anti-Inflammatory/Analgesic Properties and Phase I Clinical Trial of a New PPAR Agonist Ged-0507-34-Levo. *Gastroenterology*, **2011**, 140, S-515	13.3	2
15	Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis (UC). *Gastroenterology*, **1998**, 114, A1028	13.3	2

14	Macrophage collections in gastrointestinal biopsies and metabolic disorders: two unusual case reports. *Histopathology*, **2003**, 42, 196-8	7.3	2
13	Effect of intrajejunal elemental diet perfusion on local secretion of soluble CD4 and CD8. *Clinical and Experimental Immunology*, **1996**, 104, 293-6	6.2	2
12	Understanding the Mechanism of 5-ASA in Treating Colonic Inflammation. *Gastroenterology and Hepatology*, **2008**, 4, 319-20	0.7	2
11	A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role of Yeasts and Fluconazole in Crohn's Disease. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	2
10	Probiotic Yeast Therapy for Irritable Bowel Syndrome. *Journal of Neurogastroenterology and Motility*, **2016**, 22, 542	4.4	2
9	Adherent invasive Escherichia coli (AIEC) strain LF82, but not Candida albicans, plays a profibrogenic role in the intestine. *Gut Pathogens*, **2021**, 13, 5	5.4	2
8	Neoboutonia melleri var velutina Prain: in vitro and in vivo hepatoprotective effects of the aqueous stem bark extract on acute hepatitis models. *BMC Complementary and Alternative Medicine*, **2018**, 18, 24	4.7	1
7	Impact of the Yersinia pseudotuberculosis-derived mitogen (YPM) on the murine immune system. *Advances in Experimental Medicine and Biology*, **2003**, 529, 133-5	3.6	1
6	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. *PLoS ONE*, **2021**, 16, e0257281	3.7	1
5	Th□apeutique nutritionnelle des maladies inflammatoires chroniques de l□intestin. *Nutrition Clinique Et Metabolisme*, **2002**, 16, 202-205	0.8	0
4	Author's reply to Comment on "A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome" by Guillaume Pineton de Chambrun et al. [Digestive and Liver Disease 2015;47:119-24]. *Digestive and Liver Disease*, **2015**, 47, 437-8	3.3	
3	Pathog□ie: aspects immunologiques, infectieux et g□□iques. *Archives De Pediatrie*, **1998**, 5, 97s-100s	1.8	
2	PPAR□*Inflammatory Bowel Diseases*, **2006**, 12, S9-S10	4.5	
1	OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn□ Disease (CD) Refractory to anti-TNF□ UNITI-1. *Gut*, **2016**, 65, A3.2-A4	19.2	